Jacques Baillargeon1, Randall J Urban2, Yong-Fang Kuo3, Holly M Holmes4, Mukaila A Raji3, Abraham Morgentaler5, Bret T Howrey6, Yu-Li Lin7, Kenneth J Ottenbacher1. 1. University of Texas Medical Branch, Department of Preventive Medicine and Community Health, Galveston, TX ; University of Texas Medical Branch, Sealy Center on Aging, Galveston, TX. 2. University of Texas Medical Branch, Sealy Center on Aging, Galveston, TX ; University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX. 3. University of Texas Medical Branch, Department of Preventive Medicine and Community Health, Galveston, TX ; University of Texas Medical Branch, Sealy Center on Aging, Galveston, TX ; University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX. 4. University of Texas, M.D. Anderson Cancer Center, Department of General Internal Medicine, Houston, TX. 5. Men's Health Boston, Harvard Medical School, Boston, MA. 6. University of Texas Medical Branch, Department of Family Medicine, Galveston, TX. 7. University of Texas Medical Branch, Department of Preventive Medicine and Community Health, Galveston, TX.
Abstract
OBJECTIVES: The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S. METHODS: We conducted a retrospective cohort study of 61,474 men aged ≥40 years, and with data available in one of the nation's largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010. RESULTS: In the 12 months before initiating treatment, 73.4% of male testosterone users received a serum testosterone test and 60.7% received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4% received a serum testosterone test and 43.3% received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests. CONCLUSIONS: A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.
OBJECTIVES: The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S. METHODS: We conducted a retrospective cohort study of 61,474 men aged ≥40 years, and with data available in one of the nation's largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010. RESULTS: In the 12 months before initiating treatment, 73.4% of male testosterone users received a serum testosterone test and 60.7% received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4% received a serum testosterone test and 43.3% received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests. CONCLUSIONS: A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.
Authors: Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi Journal: N Engl J Med Date: 2010-06-16 Impact factor: 91.245
Authors: Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin Journal: Ann Pharmacother Date: 2014-07-02 Impact factor: 3.154
Authors: Olga M Calof; Atam B Singh; Martin L Lee; Anne M Kenny; Randall J Urban; Joyce L Tenover; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2005-11 Impact factor: 6.053
Authors: Najat Ziyadeh; Daniel Fife; Alexander M Walker; Gregg S Wilkinson; John D Seeger Journal: Adv Skin Wound Care Date: 2011-01 Impact factor: 2.347
Authors: Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873
Authors: William D Finkle; Sander Greenland; Gregory K Ridgeway; John L Adams; Melissa A Frasco; Michael B Cook; Joseph F Fraumeni; Robert N Hoover Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240